Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredShares IssuedShares OutstandingShares Outstanding
Ratios

SAB Biotherapeutics (SABS) Accumulated Depreciation & Amortization (2020 - 2026)

SAB Biotherapeutics filings provide 7 years of Accumulated Depreciation & Amortization readings, the most recent being $18.1 million for Q1 2026.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 18.27% to $18.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $18.1 million, a 18.27% increase, with the full-year FY2025 number at $17.5 million, up 20.19% from a year prior.
  • Accumulated Depreciation & Amortization hit $18.1 million in Q1 2026 for SAB Biotherapeutics, up from $17.5 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $18.1 million in Q1 2026 to a low of -$23.7 million in Q2 2022.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $11.9 million (2024), compared with a mean of $8.4 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 143.19% in 2023 and later rose 18.27% in 2026.
  • SAB Biotherapeutics' Accumulated Depreciation & Amortization stood at $6.3 million in 2022, then skyrocketed by 57.87% to $9.9 million in 2023, then soared by 47.04% to $14.6 million in 2024, then rose by 20.19% to $17.5 million in 2025, then grew by 3.47% to $18.1 million in 2026.
  • The last three reported values for Accumulated Depreciation & Amortization were $18.1 million (Q1 2026), $17.5 million (Q4 2025), and $16.8 million (Q3 2025) per Business Quant data.